Insider Selling: Tempus AI (NASDAQ:TEM) Director Sells $27,487.30 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $74.29, for a total value of $27,487.30. Following the sale, the director owned 30,474 shares in the company, valued at approximately $2,263,913.46. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

NASDAQ TEM opened at $76.05 on Friday. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $89.09. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The stock has a market cap of $13.72 billion, a P/E ratio of -71.75 and a beta of 3.61. The company’s 50-day simple moving average is $71.32 and its 200 day simple moving average is $57.25.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The firm had revenue of $411.54 million for the quarter, compared to analyst estimates of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 48.29%. The business’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.46) EPS. As a group, research analysts forecast that Tempus AI, Inc. will post -1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Several hedge funds have recently made changes to their positions in the business. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. increased its holdings in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares in the last quarter. Pictet Asset Management Holding SA increased its position in Tempus AI by 2,965.7% during the third quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock worth $41,233,000 after acquiring an additional 486,493 shares during the period. Eagle Health Investments LP acquired a new stake in shares of Tempus AI during the first quarter worth $11,588,000. Finally, Swiss National Bank increased its holdings in Tempus AI by 0.3% in the 1st quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after buying an additional 600 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Lake Street Capital cut Tempus AI to a “hold” rating in a research note on Monday, July 20th. Needham & Company LLC raised their price target on Tempus AI from $75.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. JPMorgan Chase & Co. increased their price target on Tempus AI from $45.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 14th. Guggenheim boosted their target price on shares of Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Rothschild & Co Redburn started coverage on shares of Tempus AI in a report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price target for the company. Eleven investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tempus AI currently has an average rating of “Hold” and an average price target of $79.37.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.